See also this year's filing and all EDGAR filings for this company.
PDF Report 0001388320_2021_Actinium_Pharmaceuticals_Inc.pdf
Logs
| warning | Expenses in unusual place in relation to revenue | input.sec.calculation_linkbase.edgar_model_mapping | {'expenses_node': 'OperatingExpenses', 'revenue_node': 'Revenues', 'net_inc_node': 'NetIncomeLoss'} |
Graph
Absolute values for 0001388320, Actinium Pharmaceuticals Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 64,925,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 312,000 |
| 3 | remainder_Assets | 1,160,000 |
| 4 | LiabilitiesCurrent | 4,767,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 311,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 6,323,498 |
| 9 | ResearchAndDevelopmentExpense | 16,062,980 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 177,713 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 66,397,000 |
| 1 | Liabilities | 5,078,000 |
| 2 | Expenses | 22,386,478 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 61,319,000 |
| 5 | NetIncome | -22,208,765 |
| 6 | ComprehensiveNetIncome | -22,208,765 |
| 7 | BaseVar | 47,019,596 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 3.12 |
| 9 | EconomicCapitalRatio | 3.77 |
Edgar->Model Mapping
Feature Distribution
Change over Time
